14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRBP vs OBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas OBIO carries 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin).
Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY).
Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $570.6M market capitalization and -195.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRBP vs OBIO Key Questions & Quantitative Answers
As of Nov 16, 2026, Orchestra BioMed Holdings, Inc. (OBIO) is the stronger overall head-to-head candidate over Corbus Pharmaceuticals Holdings, Inc. (CRBP) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRBP carries a Unified Composite Score of 45.0/100 (HOLD) at $3.38 (N/M Forward P/E, 0.0% operating margin), whereas OBIO carries 37.5/100 (SELL) at $7.12 (N/M Forward P/E, -195.4% operating margin). Composite vs. Pillar Nuance: While CRBP currently prints a higher short-term Unified Composite Score (45.0/100 HOLD vs. OBIO 37.5/100 SELL), OBIO captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. 0.0% operating margin) and revenue trajectory (-89.4% vs. -100.0% YoY). Technical & Structure Timing Caution: CRBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.3); meanwhile OBIO trades in a Markup technical trend (BREAKOUT options phase, RSI 69.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
OBIO leads the Growth & Scale pillar: CRBP posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OBIO at -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRBP cumulative revenue shifted N/A while OBIO shifted N/A. In operating R&D and SG&A reinvestment, CRBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OBIO.
OBIO screens cheaper on headline valuation multiples. CRBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRBP (-131.5% ROE) versus OBIO (-182.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CRBP carries 197.6% implied volatility (66th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 121% Vol realized risk). By comparison, OBIO carries 70.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.15β · 82% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.